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SUMMARY 
Aim:  To report the safety and efficacy of Argon Laser Trabeculoplasty (ALT) in reducing intraocular pressure 
(IOP). 
Settings and Design: This was a retrospective study performed on 25 eyes of 25 patients.  
Methods and Materials: Consecutive patients who met the inclusion criteria for ALT were recruited from the 
ophthalmic clinic of the University College Hospital Ibadan, Nigeria and followed up for a minimum period of six 
months. Two criteria were used to define successful response. Criterion 1 was defined as IOP reduction of 3mmHg 
or more without additional intervention while criterion 2 was IOP reduction of 20% or more from the pretreatment 
IOP 
Statistical Analysis: Data was analyzed using SPSS version 16. Frequencies and means were generated to observe 
patterns of variable distribution among the patients. P value < 0.05 was considered significant. 
Results: The mean pretreatment IOP was 19.9 ±3.1mmHg, (range of 16 to 26 mmHg). Mean post treatment IOP at 6 
months was 14.9 ±2.2 mmHg, (range of 11 to 19 mmHg). Mean IOP reduction at one year was 4.6 mmHg, 
representing a 22.3% drop. There was a statistically significant greater IOP reduction in eyes (P<0.001) with higher 
pretreatment IOP. Based on criterion 1 and 2, 84.0% of the patients had successful outcome at six months while at 
one year, 76.9% were successful based on criterion one.   
Conclusion: To the best of our knowledge, this is the first study to report the efficacy of ALT in Nigerians. ALT is 
safe and effective in reducing IOP in Nigerians.  
Key messages: ALT is safe and effective in reducing intraocular pressure in this population of Nigerians 
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INTRODUCTION 
Glaucoma is the leading cause of irreversible blindness 
worldwide1,2 and in Nigeria.3 It is estimated that about 
11.1million people will be blind by 2020.4 According to 
the National Blindness Survey, glaucoma is responsible 
for 16.7% of blindness in Nigeria.3 The prevalence of 
glaucoma in West Africa and other ancestrally linked 
population ranges from 6.9-8.8% 5-8 which is quite 
higher in comparison to Caucasians. Glaucoma in West 
Africa is often associated with a higher intraocular 
pressure, more rapidly progressive, and patients usually 
present late with up to 50% of cases already blind in one 
eye at presentation.5 The tremendous scarcity of 
resources for eye care in Nigeria and the high 
prevalence of the disease results in a high rate of 
preventable glaucoma related blindness.  
 
 
Currently, lowering the intraocular pressure (IOP is the 
only proven way to prevent development and 
progression of glaucoma.4 Glaucoma can either be 
treated medically, surgically or with the use of lasers. 
The cost of medical treatment is high and oftentimes 
unaffordable. This is further complicated with the 
problem of poor compliance and unavailability of these 
medications. The uptake of surgical procedures in 
management of glaucoma in Nigeria is discouraging. 
Studies in Nigeria suggest the uptake rate to be as low 
as 8-32% of patients. 9.10 
 
Argon laser trabeculoplasty (ALT), was introduced by 
Wise and Witer in 1979 and it is a standard option in the 
clinical management of open-angle glaucoma (OAG).11 
The five-year success rate with ALT is reported to be 
50%, with a decrease of 6% to 10% per year.12 Selective 
laser trabeculoplasty was introduced as an alternative to 
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ALT by Latina and Park in 1989.13,14 In contrast to the 
ALT, SLT selectively targets the pigmented trabecular 
meshwork. Many studies have reported that both argon 
and selective trabeculoplasties are similar in terms of 
their ability to reduce intraocular pressure and their 
complication rates.15-17 
 
Argon laser trabeculoplasty has been shown to reduce 
IOP in multiple clinical studies.18-20 It is non-invasive 
unlike trabeculectomy, and it may also eliminate the 
issue of non-compliance to medications when used as 
initial treatment.18,21 This may be a useful alternative to 
medical and incisional surgical treatment of glaucoma21 
especially in resource constrained regions of Sub-
Saharan Africa.  ALT has been shown to be effective 
when used as an adjunct to medical therapy in African-
derived Caribbean individuals with glaucoma.22 To the 
best of our knowledge there has been no report on the 
efficacy and safety of argon laser trabeculoplasty in 
Nigerians. This study reports the one- year outcome of 
argon laser trabeculoplasty in Nigerians. 
 
METHODS 
This was a retrospective study performed on 25 eyes of 
25 patients who were recruited consecutively from the 
ophthalmic clinic of the University College Hospital. 
Baseline characteristics such as age, sex, history of 
hypertension, diabetes, number of antiglaucoma 
medications, and baseline IOP were collected. The 
inclusion criteria for the procedure were patients with 
primary open angle glaucoma who had uncontrolled or 
suboptimal IOP control despite maximum tolerable 
medical therapy as evidenced by progressive visual field 
defects on automated standard Humphreys visual field 
test.  Patients who had less than six months follow up, 
angle closure glaucoma or < 40 years of age were 
excluded from the study. All patients were on at least 
one anti-glaucoma medication prior to treatment. 
Ethical approval was obtained and the study complied 
with the declaration of Helsinki.  
 
Argon laser trabeculoplasty was done as an adjunct to 
medical therapy in all patients. The primary outcome 
was the IOP lowering effect of ALT at a minimum 
follow up period of six months and the secondary 
outcome was the safety of the procedure. Twenty-three 
patients (92.0%)had a minimum follow up of one year. 
Two patients were lost to follow up. 
 
Laser surgical procedure 
All laser surgical procedures were performed by O.O. 
All patients were pretreated with one drop of gutt 
brimonidine 0.2% (alphagan). One hour after 
pretreatment with 0.2% brimonidine, a drop of topical 
anaesthetic agent (tetracaine) was applied to the eye to 
be treated. With the use of a laser antireflective coated 
Goldmann two mirror lens (Ocular Instruments, 
Bellevue, WA, USA), 50 applications of 50 micrometer 
spot sized burns of 0.1s were delivered to the junction 
between the non pigmented and pigmented part of the 
trabecular meshwork. Only 180 degrees of the anterior 
chamber angle was treated at a sitting with 
approximately 25 burn applications delivered to each 
quadrant. Laser power was adjusted between 400 and 
1,200mW to produce tiny champagne bubbles. Patients 
were thereafter placed on gutt diclofenac (Voltaren 
Ophtha) 6 hourly for one week.  
 
Outcome 
Patients were evaluated at one month, six months and 
one year. At each visit, anterior segment examination, 
visual acuity and IOP measurements were performed. 
Complications such as anterior segment inflammation, 
hyphema and post laser IOP spikes were recorded on 
the proforma. IOP was measured with the Goldmann 
applanation tonometer between 9.00am and 12 noon to 
minimize the effect of diurnal variations. The mean of 2 
readings at the same sitting by a single examiner at each 
visit was recorded. Two criteria were used to define 
successful response to ALT based on an earlier study.16 
Criterion 1 was defined as IOP reduction of 3mmHg or 
more without additional intervention (glaucoma 
surgery) while criterion 2 was defined as IOP reduction 
of 20% or more from the pretreatment IOP. Bivariate 
analysis was performed to determine the association 
between baseline factors and post laser IOP drop using a 
minimum IOP drop of 6mmHg. All statistical analysis 
was performed using SPSS software 18.0 (SPSS, Inc, 
Chicago, Illinois, USA). Statistical significance was set 
at P <0.05. 
 
RESULTS 
A total of 25 eyes of 25 patients were treated during this 
period. There were 9 males (36.0%) and 16 females 
(64.0%). The mean age was 58.0±7.3 years (range of 
40.0-70.0 years). Twenty-three patients had a minimum 
follow up of one year (88.5%). Two patients were lost 
to follow up. All the patients were on medical therapy 
for glaucoma and all the patients had open angle 
glaucoma with Shaffers grade ≥3 on gonioscopy. Many 
of the patients 15 patients (60.0%) were on maximum 
tolerable medical therapy at least 3 different anti-
glaucoma medications. The mean eye-drop use was 
2.8± 0.9. Table 1 shows the baseline characteristics. 
 
Changes in intraocular pressure 
The mean IOP at baseline (prior to treatment) was 
19.9±3.1mmHg (range of 16.0-26.0mmHg).  The mean 
IOP one month after ALT was 15.6±3.2mmHg while at 
6 months the mean IOP was 14.9±2.2mmHg.  
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The mean IOP drop 6 months post treatment was 
5.1±2.0mmHg which represented 25.2% drop.  
 
Table 1 Baseline characteristics of patients who had 
Argon laser trabeculoplasty 














Family History (%) 
 
13 (52.0) 
  3 (12.0) 
 2 ( 8.0) 







 8 (32.0) 
 7 (28.0) 
 8 (32.0) 
 
Table 2 compares the mean IOP pre-treatment with the 
mean IOP drop with time.  In the short term however, 
(one month) the mean IOP drop was 5.2±3.4mmHg 
which represented 24.6% drop, while in the long term 
(one year) the mean drop was 4.6±2.7mmHg 
representing 22.3% drop.  Figure 1 shows the IOP 
reductions after ALT at one month, six months and one 
year.  Based on criterion 1 and 2, 84.0% of the patients 
had successful outcome at six months. At one year 
based on criterion one, 76.9% of the patients had 
successful outcome while 53.8% had successful 
outcome based on criterion two. Figure 2 shows the 
survival curve of the cohort of patients based on 
criterion one. 
 
Table 2 Comparison of the mean pretreatment IOP with 
mean IOP drop based on time 




Mean IOP Pre-treatment 19.9±3.1  
Mean IOP at one month  15.6±3.2 <0.01 
Mean IOP at six months 14.9±2.2 <0.01 
Mean IOP at one year 15.5±2.7 <0.01 
Mean IOP Drop at one month 5.2±3.4 <0.01 
Mean IOP Drop at six months 5.1±2.0 <0.01 
Mean IOP Drop at one year 4.6±2.7 <0.01 
Mean % IOP Drop at one month 24.6±17.2 <0.01 
Mean % IOP Drop at six month 25.2±9.1 <0.01 
Mean %IOP drop at one year 22.3±12.9 <0.01 
 
Factors Affecting Intraocular Pressure Lowering 
The level of IOP before ALT was a significant factor 
affecting the IOP reduction. Patients who had IOP 
greater than 20 mmHg before ALT had more IOP 
reduction (6-8mmHg) compared with patients who had 
less than 20mmHg (0-5mmHg). Patients with higher 
pressures had more pressure reduction than patients 
with lower pre-ALT IOP. (Table 3).  
Other factors such as gender, family history, 
hypertension and diabetes did not influence IOP 




Figure 1 Mean Intraocular Pressure changes with time 
 
 
Figure 2 Shows the survival curve of the cohort of 
patients based on criterion one 
 
In multivariate analysis, the only predictor of 
postoperative IOP was the IOP before ALT such that 
patients who presented with IOP of ≥21mmHg had an 
IOP reduction of >5mmHg from the baseline and this 
was statistically significant. (P<0.001, F=27.6) 
 
Table 3 The bi variate analysis of the relationship 
between baseline factors and intraocular pressure drop 




Gender 0.76 0.38 
Family History 1.70 0.19 
Hypertension 1.06 0.30 
Diabetes 0.15 0.6 
IOP before ALT 13.09  <0.001 
0     1           6           12 months 
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There was no case of hyphema during and after the 
procedure, all patients had minimal inflammation in the 
early post-operative period which was managed with 
anti-inflammatory drops and only 2 patients (8.0%) had 




Several studies have documented the efficacy and 
acceptability of ALT in the management of patients 
with open angle glaucoma especially among Caucasians 
and Asians.18-20 To the best of our knowledge, this is the 
first study to document the efficacy of ALT in an 
indigenous Nigerian population. All the patients in our 
study had POAG and were all on anti-glaucoma 
medications before ALT procedure. 
 
ALT is known to cause reduction of IOP by increasing 
aqueous outflow. One mechanism through which it does 
this is by mechanically tightening the trabecular 
meshwork lamellae thereby opening up the inter-
trabecular spaces.23,24 Another mechanism is by cellular 
activation of the trabecular meshwork which leads to an 
increase in the number of cells involved in maintaining 
the trabecular meshwork flow.25,26 
 
We reported one-year success rate in 23 patients 
(92.0%) where success was defined as a ≥20% drop in 
IOP from baseline. Success rates after ALT depends on 
the definition of success and the IOP control also varies 
with time.19,27,28 The mean IOP reduction in our study 
was low compared with other studies. The glaucoma 
laser treatment trial reported a mean IOP drop of 9 
mmHg after primary ALT18 while the Moorfields 
primary treatment trial29 reported an IOP reduction of 
14mmHg after 6 months from a high pre-treatment IOP 
of 35mmHg. Others have reported values ranging from 
5.9 to 12.1mmHg.21,30,31 Agarwal et al in India20 
performed ALT in 40 eyes of 21 patients. Compared to 
our study the pre-laser IOP was much higher 
(25.8mmHg) and this reduced to 17.8mmHg in 6 
months suggesting an 8mmHg reduction.  One 
explanation for this, is the relatively higher baseline 
intraocular pressures in all these studies compared with 
our study which had a lower baseline IOP.  
 
Initial ALT treatment has been shown to be as 
efficacious as initial treatment with topical 
medications.19 ALT has been a standard therapeutic 
procedure in open angle glaucoma.26 Some investigators 
reported that the 5-year success rate of ALT is 50% with 
a 6% to 10% decrease every year.32,33 Spaeth et al28 
however reported that ALT could control IOP for 5 
years in about one third of cases. 
 
This study demonstrated that ALT is effective in 
lowering IOP from baseline with minimal complications 
in Nigerians. This is similar to a study done by Damji et 
al15 who reported less anterior chamber patients who 
had ALT compared with SLT. Another study34 however 
reported a higher frequency of anterior chamber 
inflammation in patients who had ALT compared with 
SLT.  Both studies however reported a very low rate of 
complications which is similar to our study.  Our results 
showed that a higher baseline IOP was associated with 
more IOP reduction and this was statistically significant. 
In a study on the effect of ALT in the Early Manifest 
Glaucoma Trial,35 the authors reported that the pre-
treatment IOP was the most important factor influencing 
the effect of treatment. They found that for every 1 
mmHg higher IOP there was a 2-3mmHg greater 
pressure reduction. This finding has also been reported 
in other studies.15, 16 All other variables such as gender, 
family history, hypertension and diabetes did not 
influence the level of IOP reduction. This may suggest 
that these baseline factors do not influence trabecular 
meshwork response to laser treatment. 
 
Although studies have shown that ALT and SLT have 
similar outcomes in terms of IOP reduction potential, 
biological effects and complication rates,16,36,37 SLT still 
has the advantage of repeatability. ALT is known to 
cause coagulation damage and scarring of the trabecular 
meshwork.15 Repeat treatment may therefore lead to 
scarring and excess damage which can lead to increased 
IOP and subsequent inefficacy in repeat 
trabeculoplasties.15  
 
Majority of studies on the efficacy of ALT have been 
reported in Caucasians.15,18,19,27 Although there are other 
modalities of managing glaucoma such as medical and 
filtering surgeries, they are associated with some 
challenges that make laser management especially 
desirable in many parts of sub-Saharan Africa. The 
issues of drug compliance, availability and affordability 
of antiglauoma drugs make medical management less 
desirable in this part of the world. Filtering surgery has 
been advocated in this population,38 however, it has 
some disadvantages which include scarring of the bleb 
with time, faster progression of cataracts, and the life- 
long risk of endophthalmitis.21 There are some 
limitations to this study. This includes the small sample 
size and the short follow up period of the patients.   
 
All the patients in this study were on medical 
management for their glaucoma hence ALT was used as 
an adjunct.  It will be interesting to perform another 
study in indigenous Nigerian population using ALT as 
primary treatment of glaucoma and following up the 
patients for a longer period.  
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CONCLUSIONS AND RECOMMENDATION 
This study adds to the body of knowledge and 
demonstrates that ALT is effective in this population of 
Nigerians with minimal complications. The procedure 
may also be used to defer the need for filtration surgery 
in this population. We recommend it as an alternative 
treatment option in patients with suboptimal IOP 
control.  More studies are needed to report the long-term 
efficacy of ALT in Nigerians.  
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